Development of devices for retinal protection

我们的目标是创造一种新的设备，可以分泌一种保护视网膜和抑制脉络膜新生血管(CNV)的药物。我们还着眼于药物的缓释、装置的安全性和易于取出的装置。装置由缓释膜和储液器制成，使用三乙二醇二甲基丙烯酸酯(TEGDM)、聚乙二醇二甲基丙烯酸酯(PEGDM)和胶原蛋白颗粒进行紫外线照射。当我们将Vasohibin-1用于负载药物时，我们发现释放的Vasohibin-1在体外抑制内皮细胞(HUVEC)的增殖。我们将该装置放在大鼠巩膜上，用强激光凝固法检测大鼠CNV模型，通过荧光素照相和CNV面积的测量，与非血管抑素释放装置相比，其效果显著。该装置的制作可以使结果准确地达到药物的缓释。我们可能会将该设备用于经巩膜外给药，用于治疗视网膜疾病。

We aimed the creation of a new device that secretes a drug for retinal protection and suppresion of choraidal neovascularization (CNV). We also aimed the sustained delivery of the drug, safety of the device and easily to be taken out the devices.The devices were made from a sustained-release film and the reservoir using triethylene glycol dimethacrylate (TEGDM), polyethylene glycol dimethacrylate (PEGDM), and collagen particles with UV irradiation. When we used vasohibin-1 for the loaded drug in the devices, the released vasohibin-1 was found to inhibit the proliferation of endothelial cells (HUVEC)in vitro. We put the device on rat sclera and examined for a rat model of CNV using intense photocoagulation, and the effect was considered significantly when compared to that of non-vasohibin releasing device by fluorescein photography and measurement of the CNV area. Fabrication of the device can make the results exactly the sustained release of drug. We may be abe to use the device from transscleral drug delivery one for retinal diseases.